Antiphospholipid antibody role in Acute Ischemic Stroke patients with COVID-19: A narrative review
- Author:
Arnaz Adisaputra
1
;
Salsa Nurfadilla
1
;
Andry Gonius
1
Author Information
- Publication Type:Journal Article
- MeSH: Ischemic Stroke; COVID-19; Antiphospholipid Syndrome; Antibodies, Antiphospholipid
- From: Acta Medica Philippina 2022;56(13):5-11
- CountryPhilippines
- Language:English
- Abstract: Antiphospholipid antibodies (aPL) are commonly found in humans after an infection. Its action can promote thrombosis via the activation of endothelial cells, platelets, and neutrophils. This autoantibody is the leading cause of antiphospholipid antibody syndrome (APS), characterized by widespread thrombosis in various vascular beds. COVID-19 also causes acute ischemic stroke (AIS) in the younger demographic, who previously was not considered a population at risk for AIS, which may be related to APS. This narrative review will discuss the role of aPL in COVID-19 patients who experienced AIS during infection.
- Full text:3430-Article Text-38248-2-10-20220729.pdf
